Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (11377)	8/18/1999 2:30:00 PM
From: Slugger	Respond to of 17367

If the midterm results are good enough in the trauma study could XOMA send those along with the meningo. study just to bolster their case? If the results in the meningo. study are borderline it might be worth it.

To: aknahow who wrote (11377)	8/18/1999 8:26:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

CVTX up $1 1/4, up 16%... www3.techstocks.com ... they are planing to go to FDA in 2001... ...check the business wire news and will find the phase III results, with p and the like... Is Only Xoma required to be mute?

To: aknahow who wrote (11377)	8/18/1999 8:55:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

George w, the trauma trial could give very good answers with 800 plus patients if the previous 400 patients trial is confirmed, a statistically significant decrease in pneumonia /ards complications. The numbers are more than enough for that purpose. Decrease in mortality/ventilator days/hospital days/costs was not significant in the FOUR HUNDRED patients trial and to show the desired results in 800 or 1600 is less likely than good results in the Meningo trial (my view, of course).